Evaluation of Tacrolimus Concentrations and Clinical Outcomes Between Extended and Immediate Release Formulations in Kidney Transplant
Journal of Pharmacy Practice · 2024
DOI: 10.1177/08971900241248862 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Pharmacy Practice, 2024. Verfasst von Hannah Naguib und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pharmacy, Indiana University Health Adult Academic Health Center, Indianapolis, IN, USA. Hauptthemen laut MEDLINE: Tacrolimus, Kidney Transplantation, Immunosuppressive Agents, Delayed-Action Preparations. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 15 Literaturangaben.
Abstract (Originalsprache)
Objectives
Tacrolimus remains the mainstay of immunosuppression in kidney transplantation. Understanding the relationship between therapeutic tacrolimus levels and outcomes of acute rejection, patient/graft survival, and tolerability are important. The relationship between time to therapeutic tacrolimus levels and outcomes has not been well established, specifically with the use of extended release tacrolimus formulation (LCP-Tac). This study investigated time to therapeutic tacrolimus levels of 2 tacrolimus formulations, LCP-Tac and immediate release tacrolimus (IR-Tac), as a predictor of clinical outcomes.
Methods
This was a single-center, retrospective, cohort study of kidney transplant recipients at Duke Hospital between 2013-2021. The primary objective evaluated the difference in time to therapeutic tacrolimus levels with LCP-Tac vs IR-Tac regimens. Secondary endpoints included time within therapeutic range during the first 3 months post-transplant, incidence of biopsy-proven rejection, development of de novo donor specific antibodies, and patient and allograft survival at 12 months post-transplant.
Results
128 patients were included (63 in LCP-Tac group and 65 in IR-Tac group). The time to therapeutic tacrolimus level was similar between formulations (7.2 days with LCP-Tac compared to 6.7 days with IR-Tac, P = .63). The time within therapeutic range during the first 3 months post-transplant, via modified Rosendaal, was similar with LCP-Tac and IR-Tac (56.1% vs 64.8%, respectively). Rates of biopsy-proven acute rejection at 12 months were similar (7/63 (11.1%) compared to 4/65 (6.2%)). There was no difference in patient/graft survival between groups.
Conclusions
The time to therapeutic tacrolimus levels did not differ based on tacrolimus formulation and was not correlated with clinical outcomes.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Pharmacy, Indiana University Health Adult Academic Health Center, Indianapolis, IN, USA.
- Department of Medicine, Duke University Hospital, Durham, NC, USA.
- Department of Pharmacy, Duke University Hospital, Durham, NC, USA.
- Department of Biostatistics and Bioinformatics, Duke University, Durham, NC, USA.
ORCID-Profile: Lexie Z Yang, Jennifer Byrns
Zitieren
APA
Naguib, H., Katz-Greenberg, G., Harris, M., Gommer, J., Yang, L. Z., Erkanli, A., & Byrns, J. (2024). Evaluation of Tacrolimus Concentrations and Clinical Outcomes Between Extended and Immediate Release Formulations in Kidney Transplant. Journal of Pharmacy Practice. https://doi.org/10.1177/08971900241248862
Vancouver
Naguib H, Katz-Greenberg G, Harris M, Gommer J, Yang LZ, Erkanli A, et al. Evaluation of Tacrolimus Concentrations and Clinical Outcomes Between Extended and Immediate Release Formulations in Kidney Transplant. Journal of Pharmacy Practice. 2024. doi:10.1177/08971900241248862
BibTeX
@article{Naguib2024,
author = {Naguib, Hannah and Katz-Greenberg, Goni and Harris, Matt and Gommer, Jennifer and Yang, Lexie Z and Erkanli, Alaattin and Byrns, Jennifer},
title = {Evaluation of Tacrolimus Concentrations and Clinical Outcomes Between Extended and Immediate Release Formulations in Kidney Transplant},
journal = {Journal of Pharmacy Practice},
year = {2024},
doi = {10.1177/08971900241248862}
}
EUVIMED